These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29026947)

  • 21. Current Role of FDG-PET in Pediatric Hodgkin's Lymphoma.
    Kluge R; Kurch L; Georgi T; Metzger M
    Semin Nucl Med; 2017 May; 47(3):242-257. PubMed ID: 28417854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathology peer review from the perspective of an external peer review pathologist.
    Mann PC
    Toxicol Pathol; 1996; 24(5):650-3. PubMed ID: 8923692
    [No Abstract]   [Full Text] [Related]  

  • 23. PET imaging in lymphoma.
    Hutchings M
    Expert Rev Hematol; 2009 Jun; 2(3):261-76. PubMed ID: 21082968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Omitting radiotherapy after attaining FDG PET-negative status following chemotherapy alone for Hodgkin lymphoma: a randomized study caveat.
    Yahalom J
    Leuk Lymphoma; 2007 Sep; 48(9):1667-9. PubMed ID: 17786699
    [No Abstract]   [Full Text] [Related]  

  • 25. FDG-PET as a biomarker for early response in diffuse large B-cell lymphoma as well as in Hodgkin lymphoma? Ready for implementation in clinical practice?
    Zijlstra JM; Burggraaff CN; Kersten MJ; Barrington SF;
    Haematologica; 2016 Nov; 101(11):1279-1283. PubMed ID: 27799345
    [No Abstract]   [Full Text] [Related]  

  • 26. The use of interim (18)F-fluorodeoxyglucose PET to guide therapy in lymphoma.
    Araf S; Montoto S
    Future Oncol; 2013 Jun; 9(6):807-15. PubMed ID: 23718301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Positron Emission Tomography Scanning in the Management of Hodgkin Lymphoma Patients: A Single-Institution Experience.
    Zabrocka E; Sierko E; Wojtukiewicz MZ
    Adv Clin Exp Med; 2016; 25(6):1185-1192. PubMed ID: 28028972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concordance in the interpretation of PET after chemotherapy in advanced stage Hodgkin lymphoma.
    Kobe C; Kuhnert G; Haverkamp H; Fuchs M; Kahraman D; Eich HT; Kriz J; Baues C; Nast-Kolb B; Bröckelmann PJ; Borchmann P; Drzezga A; Engert A; Dietlein M
    Nuklearmedizin; 2015; 54(6):241-6. PubMed ID: 26388152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone marrow signal during PET imaging in Hodgkin lymphoma.
    Fyfe A; McKay P; Leach M
    Br J Haematol; 2010 Apr; 149(2):165. PubMed ID: 20015301
    [No Abstract]   [Full Text] [Related]  

  • 30. [¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies.
    Terezakis SA; Hunt MA; Kowalski A; McCann P; Schmidtlein CR; Reiner A; Gönen M; Kirov AS; Gonzales AM; Schöder H; Yahalom J
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):615-22. PubMed ID: 20933343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. End-of-treatment FDG-PET lacks usefulness in Hodgkin lymphoma.
    Adams HJ; Kwee TC
    Ann Hematol; 2016 Dec; 95(12):2083-2084. PubMed ID: 27590600
    [No Abstract]   [Full Text] [Related]  

  • 32. Positron emission tomography/computed tomography in the management of Hodgkin's disease and non-Hodgkin's lymphoma.
    Rodríguez-Vigil B; Gómez-León N; Pinilla I; Hernández-Maraver D; Coya J; Martín-Curto L
    Curr Probl Diagn Radiol; 2006; 35(4):151-63. PubMed ID: 16814002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of positron emission tomography with [18F] 2-fluoro-D-2-deoxyglucose (FDG-PET) in Hodgkin and non-Hodgkin's lymphoma.
    Chiusolo P; Sica S; Leone G
    Hematology; 2003 Dec; 8(6):403-8. PubMed ID: 14668036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent advances in Hodgkin lymphoma: interim PET and molecular-targeted therapy.
    Nagai H
    Jpn J Clin Oncol; 2015 Feb; 45(2):137-45. PubMed ID: 25489004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Effect of Interim FDG-PET-guided Response-Adapted Therapy in Pediatric Patients with Hodgkin's Lymphoma (HL-14) : Protocol for a Phase II Study.
    Koga Y; Baba S; Fukano R; Nakamura K; Soejima T; Maeda N; Sunami S; Ueyama J; Mitsui T; Mori T; Osumi T; Sekimizu M; Ohki K; Tanaka F; Kamei M; Fujita N; Mori T; Saito AM; Kada A; Kobayashi R
    Acta Med Okayama; 2018 Aug; 72(4):437-440. PubMed ID: 30140095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma.
    Delbeke D; Stroobants S; de Kerviler E; Gisselbrecht C; Meignan M; Conti PS
    Oncologist; 2009; 14 Suppl 2():30-40. PubMed ID: 19819922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A rare case of primary thymic Hodgkin lymphoma in an elderly patient detected by 18F-FDG PET/CT.
    Treglia G; Lococo F; Petrone G; Stefanelli A; Carnassale G; Calcagni ML; Granone P; Giordano A
    Clin Nucl Med; 2013 May; 38(5):e236-8. PubMed ID: 23377412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overview of early response assessment in lymphoma with FDG-PET.
    MacManus MP; Seymour JF; Hicks RJ
    Cancer Imaging; 2007; 7(1):10-8. PubMed ID: 17766210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current clinical evidence on interim fluorine-18 fluorodeoxy glucose positron emission tomography for advanced-stage Hodgkin lymphoma and diffuse large B-cell lymphoma to predict treatment outcomes.
    Terasawa T; Nagai H
    Leuk Lymphoma; 2009 Nov; 50(11):1750-2. PubMed ID: 19863179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDG-PET scan and treatment planning for early stage Hodgkin lymphoma.
    Specht L
    Radiother Oncol; 2007 Nov; 85(2):176-7. PubMed ID: 17920143
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.